Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 243

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 243
---
’s named executive officers has been adjusted to give retroactive effect to the Reverse Stock Split and Exchange Ratio. Unless otherwise indicated, as used in this section, “Tvardi,” the “Company,” “we,” “us” and “our” refer to Legacy Tvardi prior to the closing of the Merger and Tvardi Therapeutics, Inc. after the closing of the Merger. For the year ended December 31, 2024, Legacy Tvardi’s named executive officers were: • Imran Alibhai, Ph.D., Chief Executive Officer and Director; • John Kauh, M.D., Chief Medical Officer; and • Dan Conn, J.D., M.B.A., Chief Financial Officer. For the year ended December 31, 2024, Cara’s named executive officers were: • Christopher Posner, President and Chief Executive Officer; • Ryan Maynard, Chief Financial Officer; and • Scott Terrillion, General Counsel, Secretary and Chief Compliance Officer. 2024 Summary Compensation Tables The following table presents all of the compensation awarded to or earned by or paid to Tvardi’s named executive officers for their service at Legacy Tvardi prior to the Merger.

| Name and Principal Position                              | ​ | ​ | Year |   |      |   | ​ | ​ |  Salary($) |   |         |   | ​ | ​ |   Bonus($) |   |         |   | ​ | ​ | Optionawards($)(1) |   |   |   | ​ | ​ | All othercompensation($)(3) |   |        |   | ​ | ​ | Total($) |   |         |   | ​ |
|:---------------------------------------------------------|:--|:--|-----:|:--|-----:|:--|:--|:--|-----------:|:--|--------:|:--|:--|:--|-----------:|:--|--------:|:--|:--|:--|-------------------:|:--|:--|:--|:--|:--|----------------------------:|:--|-------:|:--|:--|:--|---------:|:--|--------:|:--|:--|
| Imran Alibhai, Ph.D.Chief Executive Officer and Director | ​ | ​ |    ​ | ​ | 2024 | ​ | ​ | ​ |          ​ | $ | 551,050 | ​ | ​ | ​ |